Cantargia completed the rights issue in Q2, bringing in SEK75m before costs and entering into a loan agreement for another estimated SEK57m. This is earmarked for a phase Ib study of nadunolimab in pancreatic cancer in combination with the RAS inhibitor daraxonrasib, which is set to start in Q1 after the latter is approved, expected in H2 2026. We make some changes to our Fair Value in this update based on the new development plan for nadunolimab together with daraxonrasib and the increased focus on hematologic (blood) cancer. The Cantargia share screens as “Attractively Priced”.
LÄS MER
